Purpose: Recent studies suggest that tumor microenvironment (stroma) is important in carcinogenesis and progression. We sought to integrate global genomic structural and expressional alterations in prostate cancer epithelium and stroma and their association with clinicopathologic features.
Introduction
Previous studies have mainly focused on changes in the epithelium, but recent investigations have highlighted the tumor microenvironment as equally important in carcinogenesis and progression. Genetic changes in tumor stroma have been reported by several independent groups working on a range of solid tumors (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) , although typically, only selected markers have been used in most of these studies to assess LOH/allelic imbalance (AI).
In prostate cancer, it has also been suggested that tumor microenvironment plays an important role in the progression, acquisition of androgen independence, and distant metastases (20) (21) (22) . Tumor-microenvironment interactions through diffusible soluble factors such as TGF-b, as well as the extracellular matrix, likely lead to the development of metastasis (20) . Nonetheless, little is known about the genetic basis of the human prostate tumor microenvironment; one report described genotypic heterogeneity in mesenchymal cells with a small number of markers (9) and another showed allelic losses in the stromal component with a small number of samples and markers (23) . These findings suggest that genetic alterations in prostate cancer stroma exist and may be biologically relevant.
To attain a global perspective of epithelial and stromal specific LOH/AI changes for prostate cancer and further refine our understanding of the LOH/AI regions, we conducted a genome-wide LOH/AI scan using 381microsatel-lite markers and subsequently integrated these structural data with publicly available and experimental expressional array analyses. We also sought to determine whether compartment-specific LOH/AI could be correlated with clinicopathologic features. Finally, we conducted two types of validation: functional genomic validation and immunohistochemistry in an independent series of prostate cancer.
Materials and Methods

Patients and samples
We obtained 116 prostate cancer samples at any tumor classification with or without lymph node metastasis and analyzed them in accordance with the respective Institution's Human Subjects Protection Committees. All slides were rereviewed by a single genitourinary pathologist (P. Zheng). Clinical information such as Gleason score, tumor volume, and the status of lymph node metastasis was noted (Supplementary Table S1 ). An independent validation series of prostate cancer is described under Immunohistochemical Analysis.
Laser capture microdissection and genome-wide LOH/ AI scan
Laser capture microdissection of nonneoplastic normal tissue, epithelial carcinoma cells, and tumor-associated stroma was conducted from formalin-fixed, paraffinembedded tissue for all 116 cases, as previously described (7, 8, 17, 24, 25) and showed at the link http://www.nejm. org/doi/full/10.1056/NEJMoa071825. Stromal fibroblasts resided in between aggregations of epithelial tumor cells or no more than 0.5 cm distant from tumor nodule. While epithelial-stromal cell cross-contamination is a possibility, we used standard and well-established protocols to minimize this, as reported previously (8, 18, 24, 25) . Corresponding normal DNA for each case was procured from normal tissue, located a distance away from the tumor or from a different tissue (formalin-fixed, paraffin-embedded) block containing only normal tissue (latter being the first choice). Genomic DNA was extracted as previously described, with the exception that incubation in proteinase K was done at 65 C for 2 days (7). Primer sets for multiplex PCR defined 381 microsatellite markers in 72 multiplex panels (Research Genetics, Invitrogen). Genotyping, analyses, and scoring of LOH/AI were done as reported (24, 26, 27) . The methodologic veracity of LOH/AI scan using multiplex PCR on archived templates was extensively validated as published, that is, by a series of control experiments using chromogenic in situ hybridization (CISH), quantitative PCR, to eliminate the possibility of epithelial-stromal cell cross-contamination and to exclude any possibility of PCR artifact (24, 25) .
Data analysis
The data set contains LOH/AI status at 381 microsatellite markers for 116 different samples, each with neoplastic epithelium, tumor stroma, and normal tissue. The same 10 markers were never informative in at least one compartment and so excluded from further analyses. First, we sought to define regional LOH/AI hot/cold spots as the markers with significantly higher or lower frequency of LOH/AI compared with the average frequency of the markers along the same chromosome. We analyzed hot and cold spots of LOH/AI together with the concept that the genetic endpoint may be similar, for example, loss of a tumor suppressor gene and gain (cold spot) of an oncogenic event. Toward those ends, for each informative marker, the statistical significance of overall (across all samples) LOH/AI frequency compared with the respective chromosome average was analyzed using the exact binomial test (R base package binom.test; http://www.r-project.org). Second, the associations of LOH/AI across all informative markers (not just hot/ cold spot markers) in epithelial and stromal samples with presenting clinicopathologic features (i.e., Gleason score, tumor volume, and the status of lymph node metastasis) were analyzed using a logistic model with LOH frequency as an outcome and each clinicopathologic feature as a predictor (28, 29) . Multiple testing adjustment was applied by controlling false-positive report probability (FPRP; ref. 30 ) with a prior probability of 0.05 or 0.01. The FPRP indicates the probability that a statistically significant finding is a false positive by considering 3 factors: the P value magnitude, the statistical power, and the prior probability of true associations. Only those with P values <0.05 and estimated FPRP values less than 50%, indicating a small probability of being a false positive, are reported as statistically significant findings. An FPRP value with a prior probability of 0.05 and less than 50% is denoted as FPRP 0.05 <0.5. We used more strict criteria, FPRP 0.01 <0.1, for LOH/AI hot/cold spots expecting higher significant regions. For the association of LOH/AI with clinicopathologic features, we applied FPRP 0.05 <0.5.
Translational Relevance
Genome-wide LOH/allelic imbalance (AI) analysis of DNA from epithelium and stroma of 116 prostate cancers revealed 43 LOH/AI hot/cold spots, 17 in both epithelium and stroma (P < 0.001), 18 only in epithelium (P < 0.001), and eight only in stroma (P < 0.001). Integration of experimentally derived transcriptome data of genes within the significant LOH/AI hot/cold spots in stroma revealed 15 LOH/AI markers that were associated with Gleason score. Independent immunohistochemical validation of one of these identified STIM2 genes within a stromal significant LOH marker (identified as associated with Gleason grade) confirmed its downregulation in the transition from moderate to high Gleason grade. Stromal genomic and transcriptomic alterations may be helpful in pinpointing aggressive prostate cancers. (Continued on the following page)
For the positive correlation of LOH/AI with Gleason score, P value is obtained by one-side trend test (R, prop.trend.test) with false discovery rate (FDR) being controlled for correcting multiple testing.
Integration of public microarray data with LOH/AI data Raw data from Gene Expression Omnibus (GEO) series GSE3325 at GEO platform GPL570 (Affymetrix HGU133_Plus_2) were downloaded (31) and normalized using Robust Multi-array Averaging (RMA; ref. 32). The GSE3325 data included 13 individual benign, primary, and metastatic prostate cancers and 6 pooled samples from benign, primary, or metastatic prostate cancers. These specimens were grossly dissected maintaining at least 90% of the tissue of interest, based on examination of the frozen sections of each tissue block. We integrated microarray data of the genes residing within the regions that showed significant LOH/AI with our genetic data. We sought to use the expression microarray data to validate our LOH/AI hot/cold spots and to identify the significant genes and pathways in prostate carcinogenesis or progression. Throughout this study, we consistently selected all genes, that are located within 250 kb upstream and downstream of the LOH/AI regions of interest (significant hot/cold spots), that have significant expression values, and that are included in each microarray data set, for hierarchical clustering analyses. All hierarchical clustering analyses in this study were conducted using Cluster and TreeView softwares (http://rana.lbl.gov/ EisenSoftware.htm; ref. 33) . Genes belonging to hot/cold spots in both epithelium and stroma or in only epithelium were selected and hierarchical clustering was conducted for both genes and samples.
Generation of prostatic stroma microarray and integration with LOH/AI data
We generated stromal microarray expression data for functional validation of our LOH/AI hot/cold spots in stroma because we could not find appropriate public microarray data sets for prostatic stroma. Stromal cells cultured from normal peripheral zone tissues (F-PZ-64, F-PZ-79, F-PZ-82, F-PZ-102, F-PZ-105) and from tumors (F-CA-31, F-CA-39, F-CA-52, F-CA-67, F-CA-93) were established and grown as previously described (34) . Total RNAs were extracted from semiconfluent cells (passages 4-5) one day after feeding fresh medium using RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions and treated 
Integration of microarray data with LOH/AI regions associated with clinicopathologic features
We selected all the genes lying within and AE250 kb of the significant LOH/AI markers associated with Gleason score or tumor volume in both epithelium and stroma. With the genes associated with Gleason score or tumor volume, a hierarchical clustering was conducted for epithelium using public microarray data, GSE3325, and for stroma using our stromal microarray data (31) .
Immunohistochemical analysis
Formalin-fixed and paraffin-embedded prostate cancer sections from 49 independent cases were immunostained with a rabbit anti-STIM2 polyclonal antibody (Abcam Inc) for STIM2 expression in prostate cancer stroma. Both Gleason grade III (G3) and Gleason grade IV and/or V (GIV/V) lesions were examined for each case. Deparaffinized tissue sections were placed in 10 mmol/L citrate buffer (pH ¼ 6.0) and were heated to 125 C in a Decloaking Chamber (BioCore Medical) for 30 seconds for antigen retrieval. These sections were then incubated with a 1:300 dilution of primary antibody overnight at 4 C, secondary antibody, and the avidin-biotin complex (VECTASTAIN Elite ABC Kit; Vector Laboratories, Inc.) and developed with diaminobenzidine. Sections were counterstained with hematoxylin. For negative controls, primary antibody was omitted. Stromal expression of STIM2 was determined by counting sum of intensities of positive stromal cells divided by area of stroma, using Image-Pro Plus 7.0 (Media Cybernetics, Inc.). Five random fields were analyzed with a magnification of 40Â. STIM2 expression in tumor stroma was divided by those in normal stroma for normalization. The statistical significance of STIM2 expression levels between GIII and GIV/V lesions was determined with Wilcoxon sign-rank test.
Results
LOH/AI hot/cold spots in prostate cancer
Overall, 371 markers across all chromosomes, ranging from 7 on chromosome 22 to 31 on chromosome 1, were analyzed: 38,460 PCR reactions (19,639 for epithelium, 18,821 stroma) were informative for LOH/AI evaluation. We identified a total of 43 hot/cold spots, 17 occurring in both epithelium and stroma, 18 only in the epithelium, and 8 only in the stroma (Table 1) . No known genes were contained at 7 loci (D1S2134, D3S2427, D4S2417, D6S1277, D9S922, D12S2078, and D14S606), however, we found expressed sequence tags (EST) at these loci (Table 1) . Genes belonging to hot/cold spots common to both epithelium and stroma include HOXB1-HOXB9 cluster, HOXB13, ZNF554, ZNF555, ZNF556, ZNF57, and ZNF77, as well as 7 miRNA (Table 1) . FGF12, ACVRIB, the KRT cluster, and APOL1-APOL4, as well as 6 miRNAs, were included in the genes lying in hot/cold spots of LOH/AI in epithelium only (Table 1) , and TGFb1I1, WFDC5, WFDC12, and TP53TG5, as well as 5 noncoding RNAs, notably miR-125b-1, were among the genes of hot/cold spots in stroma only ( Table 1) .
Association of LOH/AI with presenting clinicopathologic features
LOH/AI markers in association with clinicopathologic features (Supplementary Table S1 ) may reveal clues to clinical behavior and biologic diversity and/or serve as biomarkers of prognosis or therapeutic options. Using logistic regression, we analyzed our genome-wide LOH/ AI scan across all informative markers to identify compartment-specific loci that were significantly associated with aggressiveness of disease as reflected by Gleason score, tumor volume, and regional nodal status. We identified 15 LOH/AI regions, 10 in epithelium and 5 in stroma, associated with Gleason score (Table 2) , 11 (8 in epithelium and 3 in stroma) of which showed a positive correlation with increasing Gleason score (one-sided trend test, FDR < 0.05; Supplementary Table S2). Among these 11 markers, 8 (6 in epithelium and 2 in stroma) remained significantly positively correlated with Gleason score even when a more rigorous method was applied (Bonferroniadjusted P < 0.05). In association with tumor volume, 40 markers were identified in epithelium and 35 in stroma (Supplementary Table S3 ). Interestingly, there were no significant LOH/AI markers correlated with regional nodal metastases.
Expression profiling of genes within LOH/AI hot/cold spot regions using publicly available neoplastic epithelial microarray data
We focused on genes of LOH/AI hot/cold spot regions and analyzed their expression profiles using publicly available microarray data (see Methods). This served 2 purposes. First, this acts as a functional (transcript expressional) validation of the genetic data. Second, integration of the genetic and expressional data would lend clues to the compartment-specific functions of the genes within the hot/cold spot regions as they relate to progression and prognosis. Hierarchical cluster analysis supervised by 87 genes found in LOH/AI hot/cold spot regions AE250 kb resulted in 3 distinct groups: normal epithelium, cancer, and metastatic cancer when considering genetic information from both epithelium and stroma (Fig. 1A) . When we used 61 genes residing within the LOH/AI hot/cold spot AE250 kb regions occurring specifically in epithelium, only 2 groups could be clearly distinguished, namely, normal epithelium and metastatic cancer groups (Fig. 1B) . Interestingly, the primary cancer samples were equally clustered with normal epithelium or with metastatic disease.
Expression profiling of genes within LOH/AI hot/cold spot regions using our experimentally generated stromal microarray data
We conducted a hierarchical clustering of stromal cells, supervised by 28 genes of LOH/AI hot/cold spot AE 250 kb regions from stroma only (Fig. 2) . This accurately separated normal stromal cells and cancer-derived stromal cells.
Expression profiling of genes within LOH/AI regions associated with clinicopathologic features
We further focused on genes residing in proximity to our LOH/AI regions associated with Gleason score and tumor volume and analyzed their expression profiles using publicly available microarray data (see Methods) for epithelial analysis as well as our experimentally generated expression data for stromal analysis. With only one exception, P3, in neoplastic epithelial analysis, samples were clearly separated into normal, primary cancer, and metastatic disease by 31 genes within the LOH/AI (AE 250 kb) regions in neoplastic epithelium associated with Gleason score (Supplementary Fig. S1A ). Our stromal cell cultures derived from normal tissues and from prostate cancer were accurately clustered supervised by the 18 genes belonging to our stroma-only LOH/AI (AE 250 kb) regions associated with Gleason score (Supplementary Fig. S1B ). As for tumor volume, epithelial prostate cancer samples were also successfully separated into normal, primary cancer, and metastatic disease in epithelial analysis (Supplementary Fig.  S2A ). In contrast, our stromal cell cultures did not cluster into tumor-derived stroma and normal stroma groups in stromal analysis for tumor volume (Supplementary Fig.  S2B ).
Independent validation of candidate gene by immunohistochemical analysis
To further validate our genetic data, we selected our strongest candidate gene, STIM2, lying in D4S2397, which is the most significant stroma-associated LOH marker correlated with Gleason score (Supplementary Table S2 ). We examined STIM2 expression in 49 independent primary prostate cancer samples that had both Gleason grade III and Gleason grade IV and/or V lesions by immunohistochemical analysis (Fig. 3) . Stromal protein expression of STIM2 (y-axis) showed significant downregulation in the stroma of GIV/V lesions compared with that of GIII lesions (P < 0.001; Fig. 3A) .
Discussion
Recent molecular studies have provided a myriad of information about genetic changes in prostate cancer and accumulating data over the last 2 decades have shown the importance of the tumor stroma in prostate carcinogenesis, with the latter based on mainly functional and cell biologic studies. Here, we have completed a genome-wide LOH/AI C7  C6  FCRL1  EMP1  EMP1  EMP1  ZNF554  CARD6  CD1D  RPL37  CSNK2A1  CSNK2A1  CSNK2A1  ARSB  GOLGA1  ZNF555  DGKG  CALCOCO2  CALCOCO2  CSNK2A1  CSNK2A1  SRXN1  TBC1D20  HOXB13  HOXB13  PRKAA1  PRKAA1  PRKAA1  TBC1D20  C17orf92  MCTP2  MCTP2  SFRS5  SFRS5  C20orf54  HSPA5  SERPINI1  DMGDH  BHMT2  BHMT2  KIRREL  SMOC1  FCRL1  SMOC1  ZNF555  KNG1  NRSN2  PRKAB1  RABEPK  ARSB  FCRL2  FCRL2  ARSB  HRG  CD5L  HOMER1  CCDC60  ARSB  PXDN  PXDN  CCDC64  HRG  GRIN2B  FCRL2  RABEPK  GRIN2B  AES  GNA11  GNA11  GNA11  ZNF554  SOX12  FETUB  SOX1  ARPC5L  ARPC5L  ARPC5L  ARPC5L  DNAJB11  HOXB5  C9orf126  CIT  HOXB7  HOXB7  HOXB6  HOXB2  HOXB3  ZBBX  HOXB7  TLE6  HOXB9  PRKAB1  HOXB4  CCDC64  TRIB3  BRUNOL5  HOXB5  SOX12  TTLL6  ZNF77  ZNF77  BHMT  BRUNOL5  GAPVD1  HOXB8  HOMER1  KIAA0247  HOMER1  SOX1  SERPINI2  WDR49  WDR49  SKAP1  SNTG2  TLE6  GAPVD1  PDCD10  GAPVD1  GAPVD1  TBCCD1  TLE2  TLE2  GOLGA1  PPP6C  PPP6C  ZNF57  AHSG  CRYGS  FCRL2  GNA15  AHSG  KNG1  NCLN  HOXB3  TCF15  ZNF556  HOXB8  S1PR4  EMP1  HOXB1  KIRREL  SLC10A1  KIRREL  C20orf54  TPO  C13orf28  ZNF555  HOXB9  ZNF555  RBCK1  RBCK1  TRIB3   N2  N1  N3  N4  NX1  NX2  P3  P4  P1  P2  PX1  PX2  P5  W1  W2  WX1  WX2  W3  W4   A   BANP  BANP  BANP  ACVR1B  SSH2  CA5A  ANKRD28  ERRFI1  KRT75  AADAC  SSH2  C12orf44  SSH2  HTR7  KRT83  KRT86  KLF5  ANKRD28  ANKRD28  SLC7A5  TMEM181  BLMH  MCM6  SSH2  KRT80  MCM6  JPH3  TULP4  TULP4  TULP4  KLHDC4  DDT  SUCNR1  LCT  GRASP  JPH3  APOL2  SYNJ2  SLC6A4  ZRANB3  CABIN1  CABIN1  KRT81  NR4A1  EFCAB5  KRT82  SUSD2  SUSD2  UTS2  APOL1  APOL3  GGT5  BTD  APOL2  GSTT1  HTR7  ACVR1B  ACVR1B  SYNJ2  APOL4  APOL4  SYNJ2  GTF2H5  SERAC1  SYNJ2  SYNJ2  KRT85  MYH9  FGF12  FGF12  FGF12  EFCAB5  SLC6A4  HTR7  JPH3  HTR7  SLC6A4  ACVR1B  GSTT2  BTD  NR4A1  SPECC1L  APOL4  KRT7  PARK7  HACL1  UBXN4  UBXN4  UBXN4  C3orf59  RBM9  DARS  DARS  CCDC55  RBM9  PER3  RBM9  PER3  ZRANB3  KLF5  R3HDM1  TNFRSF9  UTS2  KRT6B  PER3  TNFRSF9   N2  N1  N3  N4  NX1  NX2  P2  P5  PX1  PX2  P1  P4  P3  W1  W2  W3  W4  WX1 scan and integrated these data with global expression array data for prostate cancer epithelium and stroma and correlated these with presenting clinicopathologic features and validated our observations via functional genomics approach and immunohistochemistry of a newly identified stroma-relevant gene associated with Gleason score. First, genome-wide LOH/AI scan revealed LOH/AI hot/ cold spots that were important in each compartment alone and in both compartments. Among the 225 genes in proximity to the 43 LOH/AI hot/cold spot regions germane to epithelium and/or stroma, several candidate tumor suppressor genes, such as HOXB13 (epithelium and stroma), the APOL1-4 cluster and ACVR1B (epithelium), and TP53TG5 (stroma), are notable. The APOL family of genes (APOL1-6) encodes programmed cell death proteins that can initiate apoptosis or autophagic cell death, as well as belong to a multicomponent innate immunity complexbuilding platform (35) . Thus, loss of function of the APOL1-4 region will lead to loss of apoptosis and autophagic cell death regulation as well as potential decreased innate immunity locally. Our observations here, that is, loss of APOL1-4 function leading to loss of autophagic cell death and consequent loss of essential nutrients and energy to tumor epithelial cells in a paracrine fashion are consistent with the autophagic tumor stroma model of cancer metabolism underscored by the work of Witkiewicz and colleagues (36) . Furthermore, the relevance to innate immunity lends credence to early hypotheses of metabiomic relationships in initiating various neoplasias (35, 37) , including that of the prostate. Of note, the activin/TGF-b signaling subnetwork has already been acknowledged to be important in prostate carcinogenesis (38) . We have shown that D12S297 harbors the human activin receptor, ACVR1B, which has been described as having somatic mutations and deletions in at least 4 other types of cancers, and which is expressed in prostate epithelium (39) . ACVR1B encodes an activin receptor that signals via the TGF-b pathway as well.
Second, we found 15 specific loci of LOH/AI in the epithelium or stroma associated with Gleason score (Table  2) . We suspect that these regions and genes are relevant to invasion and progression and focused especially on stroma. Two loci (4p15.2 and 19p13.3) harbored significant LOH/ AI in the stroma, correlated with Gleason score. One of the genes located in the 4p15.2, which is the most significant region, is STIM2 (stromal interaction molecule 2). Our immunohistochemical analysis of 49 independent prostate cancer samples has given us an in-principle validation of our genetic and functional genomic studies. STIM1 was originally proposed as a candidate tumor suppressor and regulates intracellular calcium (40, 41) . STIM2 is also a transmembrane protein that, in limited studies, has been shown to mediate cellular proliferation (42) . In view of our observations, further studies on the role of STIM2 in different cancers, especially in different compartments, are required. The 19p13.3 region contains AES which is known to be associated with Wnt signaling pathway and mitogenactivated protein kinase (MAPK)/extracellular signalregulated kinase 1 (ERK1), which is an upstream kinase for NF-kB activation (43, 44) . The cluster of ZNFs including ZNF77 also at the 19p13.3 region was previously associated with different cancers, and ZNF77 status has been used as a prognostic marker in early-stage renal cell carcinomas and stage I breast cancers to predict recurrence (45, 46) .
We subsequently integrated global transcriptome data from public archives and those we experimentally derived with our LOH/AI hot/cold spots. Importantly, these provided functional validation of our genomic data. The gene expression profile using neoplastic epithelium from public sources with only genes from our epithelium-related LOH hot/cold spots, which is not the entire epithelium gene expression profile, could not accurately cluster the samples. Similarly, we also attempted the cluster analysis supervised by the genes from only stromal hot/cold spots, and as C16orf58  POL3S  MYST1  STK4  ROCK2  STX4  TGFB1I1  ZNF668  ARMC5  SYS1  VKORC1  SDC4  FMN2  KCNS1  TOMM34  SLPI  ZNF202  DBNDD2  TGFB1I1  TNS1  FUS  GREB1  SEMG1  ZNF646  GREM2  ROCK2  PYCARD  PYCARD  E2F6  YWHAB  YWHAB expected, it resulted in failure to cluster the samples (data not shown). In contrast, these samples could be accurately clustered when taking into account the genes from the stromal hot/cold spots, indicating that genomic alterations with consequent expressional alterations in the stroma are necessary and play an important role in prostate carcinogenesis and progression. Equally important is a notable negative. The genes within the LOH hot/cold spot regions identified as important in correlating with tumor volume were germane only in the epithelium. This was validated when expression data supervised by the genes within the LOH hot/cold spot regions relevant to tumor volume could not accurately classify normal stroma from tumor stroma ( Supplementary Fig. S2B ). In other words, at least in prostate cancer, tumor volume does not appear to be influenced by stromal genomic or expressional alterations of genes located within tumor volume-associated stromal LOH regions in this study. This makes teleology logical given that the genes playing roles in tumor stroma are almost certainly relevant to invasion, progression, and metastasis, as noted above. By integrating genomic and global expression data for the epithelium and stroma of prostate cancer, we were able to detect significant regions and candidate genes important in the tumor-microenvironment cross-talk that leads to carcinogenesis and progression. Importantly, we have conducted functional genomic validation of the genes in the regions associated with Gleason score as well as tumor volume, in a compartment-specific manner, as well as validated a stromal gene associated with Gleason score in an independent series of tumors using a different technique, namely, immunohistochemistry for STIM2, as proof of principle. Parenthetically, we also noted that the epithelial expression of STIM2 (D4S2397 is also a significant epithelium-associated LOH marker correlated with Gleason score as well) was downregulated in G4/5 over G3. However, we did not formally analyze the epithelial expression in this study because the effect size did not appear as marked as for stroma. These data provide fundamental insights into compartment-specific roles in prostate carcinogenesis or progression and may also reveal the solid tumor microenvironment as a novel compartment for important biomarkers of prognosis as well as targeted therapy.
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